C Collegium Pharmaceutical Inc
C
Закрыт
СекторЗдравоохранение
35.42 2.13
Обзор
Изменение цены акций
24 ч
Мин.
33.93
Макс.
36
Доход | -2.5M 14M |
|---|---|
Продажи | -12M 194M |
P/E Средняя по отрасли | 16.675 50.958 |
Прибыль на акцию | 1.76 |
Рентабельность продаж | 7.491 |
Сотрудники | 423 |
EBITDA | -213M 91M |
Рекомендации | Активная покупка |
|---|---|
Прогноз на 12 месяцев | +55.98% upside |
Следующий отчет о доходах | 6 авг. 2026 г. |
|---|
Рыночная капитализация | -6.5M 1.1B |
|---|---|
Предыдущая цена открытия | 33.29 |
Предыдущая цена закрытия | 35.42 |
Новостные настроения
By Acuity
30%
70%
79 / 342 Рейтинг в Healthcare
Collegium Pharmaceutical Inc График
Прошлые результаты не являются надежным индикатором будущих результатов.
О компании Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.